Los Angeles, CANCT06994338Now EnrollingIRB Ready

Alcohol Use Disorder Clinical Trial in Los Angeles, CA

Access cutting-edge alcohol use disorder treatment through this phase 2 clinical trial at a research site in Los Angeles. Study-provided care at no cost to qualified participants.

Sponsored by University of Southern California

Quick Self-Assessment

See if you qualify for this Los Angeles location

Preparing your pre-screening questions…

Expert Care in Los Angeles

Access alcohol use disorder specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related alcohol use disorder treatment provided free

Apply for This Los Angeles Location

Check if you qualify for this alcohol use disorder clinical trial in Los Angeles, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Los Angeles

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Los Angeles site if eligible
  4. 4Begin participation

About This Alcohol Use Disorder Study in Los Angeles

The objective of this Phase 2 randomized controlled trial is to evaluate the effects of weekly tirzepatide (vs. placebo) on alcohol consumption and cardiometabolic outcomes in adults with alcohol use disorder and overweight or obesity.

Sponsor: University of Southern California

Who Can Participate

Inclusion Criteria

Meeting past-year DSM-5 criteria for AUD with at least moderate severity (≥ 4 symptoms)
Average daily consumption of ≥40g (women) / ≥ 60 g (men) per day in the 28 days prior to baseline
Body mass index ≥ 27kg/m2
Willingness to attend weekly medication visits and complete all study procedures
Ability to read and communicate in English
Treatment-seeking (i.e., currently seeking assistance to reduce or stop drinking)
Stable housing status

Exclusion Criteria

Meeting past-year DSM-5 criteria for another substance use disorder (except tobacco use disorder or mild cannabis use disorder)
Recent (past 30 day) self-report of illicit drug use (excluding cannabis) or non-prescribed opioids; or positive urine screen for illicit drugs. A positive screen for opioids will be allowed if the participant is prescribed an opioid replacement therapy medication and can provide documentation.
History of significant alcohol withdrawal, as indicated by history of seizure, delirium tremens; history of hospitalization for withdrawal-related symptoms; a CIWA score \>9 at assessment; or a baseline score 4+ on the Prediction of Alcohol Withdrawal Severity (PAWS) scale.
Recent (past 3 months) engagement in behavioral or pharmacological alcohol use treatment or currently mandated to receive treatment
History of chronic or acute pancreatitis
History of Type 1 or Type 2 diabetes, or diabetes-related conditions (e.g., diabetic retinopathy), or baseline HbA1C ≥ 6.5%
History of suicide attempt or report of current (past 2 weeks) active suicidal ideation
Lifetime diagnosis of severe mental illness (e.g., psychosis or bipolar disorder)
Evidence of a significant anxiety or depressive disorder that is currently interfering with daily functioning, based on GAD-7 and PHQ-9 scores and physician judgement. (Anxiety or depression are not exclusionary if symptoms are stable/non-interfering with daily activities, or if the participant is receiving treatment, i.e., psychiatric medications have not changed for at least 3 months prior to baseline)
Treatment for eating disorder in the past 12 months
Report of significant medical, neurological, or psychiatric illness that would preclude safe or full study participation based on the judgement of the study physicians
History of known liver disease
Elevated serum lipase, amylase, bilirubin, or ALP, ALT, or AST (\>3x upper limit of normal range)
History of malignant neoplasms in the last 5 years, except for non-melanoma skin cancer
Inability to attend weekly clinic visits as scheduled (i.e., based on travel or work schedule)
Weight loss \> 5% in the 30 days prior to screening
Currently enrolled in another clinical trial involving an investigational product
Current contact or co-habitation with a current or former participant in the present trial
Current co-habitation with a person taking GLP-1RA therapy
Planned surgical procedures requiring anesthesia within 90 days post-entry into the study
History of treatment with tirzepatide or a GLP-1RA within 6 months of screening
Treatment with any weight loss medications (e.g., orlistat, bupropion-naltrexone) or medications known to reduce alcohol consumption (e.g., naltrexone, topiramate, acamprosate, varenicline) in the past 3 months
Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) type I or type II
Estimated glomerular filtration rate (eGFR) \<60 (indicated impaired kidney function)
Use of prescribed or non-prescribed medications that would preclude safe use of tirzepatide in the judgement of the study physicians
Known bone, muscle, or wasting conditions (e.g., osteoporosis, sarcopenia) aa. Presence of significant or uncontrolled GI conditions (e.g., GERD) that would interfere with treatment in the judgement of study physicians bb. Any other significant disease, disorder, or finding that in the opinion of the investigator(s) may increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data. cc. Currently pregnant or nursing, or inability to adhere to a reliable method of birth control (applies to female participants of childbearing age) dd. Uncontrolled hypertension at baseline, as indicated by an average blood pressure reading of \>180/110 after three successive readings ee. History of heart attack or stroke in the 6 months prior to screening ff. A pre-treatment reduction in alcohol consumption to \< 40g/day (males) or \<20g/day (females) in the interval between baseline screening and randomization

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Los Angeles?

Yes, this clinical trial (NCT06994338) has an active research site in Los Angeles, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Alcohol Use Disorder Treatment Options in Los Angeles, CA

If you're searching for alcohol use disorder treatment options in Los Angeles, CA, this clinical trial (NCT06994338) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Los Angeles research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced alcohol use disorder specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all alcohol use disorder clinical trials near you to find additional studies recruiting in your area.

More Substance Use Disorder Trials in Los Angeles, CA

See all substance use disorder clinical trials recruiting in Los Angeles — not just this study.

Browse Substance Use Disorder Trials in Los Angeles →

Browse More Trials by Condition

Substance Use Disorder TrialsAll Conditions →

Ready to Join in Los Angeles?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Los Angeles, CA